,AID,AID Version,AID Revision,Panel Member ID,SID,CID,Bioactivity Outcome,Target GI,Target GeneID,Activity Value [uM],Activity Name,Assay Name,Bioassay Type,PubMed ID,RNAi
0,155,1,1,,74745,6214,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the rad50 strain,Other,,
1,157,1,1,,74745,6214,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the mec2-1 strain,Other,,
2,161,1,1,,74745,6214,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the sgs1 mgt1 strain,Other,,
3,165,1,1,,74745,6214,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the cln2 rad14 strain,Other,,
4,167,1,1,,74745,6214,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the bub3 strain,Other,,
5,175,1,1,,74745,6214,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the mlh1 rad18 strain,Other,,
6,421,1,3,,17389859,6214,Inactive,,,,,Cell Viability - BJ,Confirmatory,,
7,426,1,2,,17389859,6214,Inactive,,,,,Cell Viability - Jurkat,Confirmatory,,
8,427,1,1,,17389859,6214,Inactive,,,,,Cell Viability - Hek293,Confirmatory,,
9,433,1,1,,17389859,6214,Inactive,,,,,Cell Viability - HepG2,Confirmatory,,
10,434,1,2,,17389859,6214,Inactive,,,,,Cell Viability - MRC5,Confirmatory,,
11,435,1,2,,17389859,6214,Inactive,,,,,Cell Viability - SK-N-SH,Confirmatory,,
12,445,3,1,,17389859,6214,Inactive,10092619.0,4792.0,,,IkB Signaling,Confirmatory,,
13,530,1,1,,17389859,6214,Inactive,2499604.0,26414.0,,,JNK3 AlphaScreen Assay,Confirmatory,,
14,540,1,1,,17389859,6214,Inactive,,,,,Cell Viability - N2a,Confirmatory,,
15,541,1,1,,17389859,6214,Inactive,,,,,Cell Viability - NIH 3T3,Confirmatory,,
16,542,1,1,,17389859,6214,Inactive,,,,,Cell Viability - HUV-EC-C,Confirmatory,,
17,543,1,1,,17389859,6214,Inactive,,,,,Cell Viability - H-4-II-E,Confirmatory,,
18,544,2,1,,17389859,6214,Inactive,,,,,Cell Viability - SH-SY5Y,Confirmatory,,
19,545,1,1,,17389859,6214,Inactive,,,,,Cell Viability - Renal Proximal Tubule,Confirmatory,,
20,546,1,1,,17389859,6214,Inactive,,,,,Cell Viability - Mesenchymal,Confirmatory,,
21,584,1,3,,17389859,6214,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
22,585,1,4,,17389859,6214,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
23,595,1,3,,17389859,6214,Inactive,,,,,qHTS Assay for Disrupters of an Hsp90 Co-Chaperone Interaction,Confirmatory,,
24,596,1,2,,17389859,6214,Inactive,92096784.0,4137.0,,,qHTS Assay for Tau Filament Binding,Confirmatory,,
25,603,1,2,,17389859,6214,Inactive,,,,,qHTS Assay for Inhibitors of DNA Polymerase III Holoenzyme System,Confirmatory,,
26,605,1,2,,17389859,6214,Inactive,84028058.0,,,,qHTS Assay for Inhibitors of YjeE,Confirmatory,,
27,654,1,1,,17389859,6214,Inactive,,,,,Cellular Toxicity (caspase-3) HepG2,Confirmatory,,
28,655,1,1,,17389859,6214,Inactive,,,,,Cellular Toxicity (caspase-3) Jurkat,Confirmatory,,
29,656,1,1,,17389859,6214,Inactive,,,,,Cellular Toxicity (caspase-3) HUV-EC-C,Confirmatory,,
30,657,1,1,,17389859,6214,Inactive,,,,,Cellular Toxicity (caspase-3) SHSY5Y,Confirmatory,,
31,658,1,1,,17389859,6214,Inactive,,,,,Cellular Toxicity (caspase-3) BJ,Confirmatory,,
32,659,1,1,,17389859,6214,Inactive,,,,,Cellular Toxicity (caspase-3) MRC-5,Confirmatory,,
33,660,1,1,,17389859,6214,Inactive,,,,,Cellular Toxicity (caspase-3) Mesangial,Confirmatory,,
34,661,1,1,,17389859,6214,Inactive,,,,,Cellular Toxicity (caspase-3) SK-N-SH,Confirmatory,,
35,662,1,1,,17389859,6214,Inactive,,,,,Cell signaling CRE-BLA (Fsk stim),Confirmatory,,
36,663,1,1,,17389859,6214,Inactive,,,,,Cellular Toxicity (caspase-3) H-4-II-E,Confirmatory,,
37,664,1,1,,17389859,6214,Inactive,,,,,Cellular Toxicity (caspase-3) Hek293,Confirmatory,,
38,665,1,1,,17389859,6214,Inactive,,,,,Cellular Toxicity (caspase-3) N2a,Confirmatory,,
39,666,1,1,,17389859,6214,Inactive,,,,,Cellular Toxicity (caspase-3) NIH 3T3,Confirmatory,,
40,667,1,1,,17389859,6214,Inactive,,,,,Cellular Toxicity (caspase-3) Renal Proximal Tubule,Confirmatory,,
41,875,1,2,,17389859,6214,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Green Fluorophore),Confirmatory,,
42,880,2,1,,17389859,6214,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
43,880,2,1,,17389859,6214,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
44,881,2,2,,17389859,6214,Inactive,317373425.0,247.0,,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
45,884,1,2,,17389859,6214,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 3A4,Confirmatory,,
46,885,1,2,,17389859,6214,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Activators of Cytochrome P450 3A4,Confirmatory,,
47,886,1,2,,17389859,6214,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
48,886,1,2,,17389859,6214,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
49,887,1,2,,17389859,6214,Inactive,1832253.0,246.0,,Potency,qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase),Confirmatory,,
50,889,1,3,,17389859,6214,Inactive,1730092.0,840.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-7,Confirmatory,,
51,892,1,2,,17389859,6214,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Red Fluorophore),Confirmatory,,
52,893,1,2,,17389859,6214,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
53,893,1,2,,17389859,6214,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
54,894,2,1,,17389859,6214,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
55,900,1,3,,17389859,6214,Inactive,15431328.0,834.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1,Confirmatory,,
56,902,1,2,,17389859,6214,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature,Confirmatory,,
57,912,1,2,,17389859,6214,Inconclusive,21392848.0,,2.5119,Potency,qHTS Assay for Anthrax Lethal Toxin Internalization,Confirmatory,,
58,921,1,2,,17389859,6214,Inactive,,,,Potency,Cell Viability - LYMP2-001,Confirmatory,,
59,923,1,2,,17389859,6214,Inactive,,,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1: Spectroscopic Profiling in AFC Spectral Region,Confirmatory,,
60,924,1,2,,17389859,6214,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature,Confirmatory,,
61,925,1,2,,17389859,6214,Inactive,4504349.0,3043.0,,Potency,qHTS Assay for Modulators of Hemoglobin Beta Chain Splicing,Confirmatory,,
62,926,1,2,,17389859,6214,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
63,938,1,2,,17389859,6214,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293,Confirmatory,,
64,946,1,2,,17389859,6214,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-001 - Dead Cells,Confirmatory,,
65,947,1,2,,17389859,6214,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-001 - Live Cells,Confirmatory,,
66,948,1,2,,17389859,6214,Inactive,,,,Potency,Cell Viability - LYMP1-002 - Assay at 16 hr,Confirmatory,,
67,955,1,2,,17389859,6214,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-002 - Live Cells,Confirmatory,,
68,960,1,2,,17389859,6214,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-002 - Dead Cells,Confirmatory,,
69,961,1,2,,17389859,6214,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-003 - Dead Cells,Confirmatory,,
70,962,1,2,,17389859,6214,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-003 - Live Cells,Confirmatory,,
71,963,1,2,,17389859,6214,Inactive,,,,Potency,Cell Viability - LYMP1-003 - Assay at 24 hr,Confirmatory,,
72,964,1,2,,17389859,6214,Inactive,,,,Potency,Cell Viability - LYMP1-003 - Assay at 40 hr,Confirmatory,,
73,965,1,2,,17389859,6214,Inactive,,,,Potency,Cell Viability - LYMP2-003,Confirmatory,,
74,966,1,2,,17389859,6214,Inactive,,,,Potency,Cell Viability - LYMP2-004,Confirmatory,,
75,967,1,2,,17389859,6214,Inactive,,,,Potency,Cell Viability - LYMP2-005,Confirmatory,,
76,968,1,2,,17389859,6214,Inactive,,,,Potency,Cell Viability - LYMP2-009,Confirmatory,,
77,969,1,2,,17389859,6214,Inactive,,,,Potency,Cell Viability - LYMP2-011,Confirmatory,,
78,970,1,2,,17389859,6214,Inactive,,,,Potency,Cell Viability - LYMP2-013,Confirmatory,,
79,971,1,2,,17389859,6214,Inactive,,,,Potency,Cell Viability - LYMP2-015,Confirmatory,,
80,972,1,2,,17389859,6214,Inactive,,,,Potency,Cell Viability - LYMP2-017,Confirmatory,,
81,973,1,2,,17389859,6214,Inactive,,,,Potency,Cell Viability - LYMP2-019,Confirmatory,,
82,974,1,2,,17389859,6214,Inactive,,,,Potency,Cell Viability - LYMP2-021,Confirmatory,,
83,975,1,2,,17389859,6214,Inactive,,,,Potency,Cell Viability - LYMP2-023,Confirmatory,,
84,976,1,2,,17389859,6214,Inactive,,,,Potency,Cell Viability - LYMP2-025,Confirmatory,,
85,977,1,2,,17389859,6214,Inactive,,,,Potency,Cell Viability - LYMP2-002,Confirmatory,,
86,978,1,2,,17389859,6214,Inactive,,,,Potency,Cell Viability - LYMP2-006,Confirmatory,,
87,979,1,2,,17389859,6214,Inactive,,,,Potency,Cell Viability - LYMP2-007,Confirmatory,,
88,980,1,2,,17389859,6214,Inactive,,,,Potency,Cell Viability - LYMP2-008,Confirmatory,,
89,981,1,2,,17389859,6214,Inactive,,,,Potency,Cell Viability - LYMP2-010,Confirmatory,,
90,982,1,2,,17389859,6214,Inactive,,,,Potency,Cell Viability - LYMP2-012,Confirmatory,,
91,983,1,2,,17389859,6214,Inactive,,,,Potency,Cell Viability - LYMP2-014,Confirmatory,,
92,984,1,2,,17389859,6214,Inactive,,,,Potency,Cell Viability - LYMP2-016,Confirmatory,,
93,985,1,2,,17389859,6214,Inactive,,,,Potency,Cell Viability - LYMP2-018,Confirmatory,,
94,986,1,2,,17389859,6214,Inactive,,,,Potency,Cell Viability - LYMP2-020,Confirmatory,,
95,987,1,2,,17389859,6214,Inactive,,,,Potency,Cell Viability - LYMP2-022,Confirmatory,,
96,988,1,2,,17389859,6214,Inactive,,,,Potency,Cell Viability - LYMP2-024,Confirmatory,,
97,989,1,2,,17389859,6214,Inactive,,,,Potency,Cell Viability - LYMP2-026,Confirmatory,,
98,993,1,2,,17389859,6214,Inactive,,,,Potency,Cell Viability - LYMP1-002 - Assay at 24 hr,Confirmatory,,
99,994,1,2,,17389859,6214,Inactive,,,,Potency,Cell Viability - LYMP1-002 - Assay at 40 hr,Confirmatory,,
100,995,1,2,,17389859,6214,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay,Confirmatory,,
101,1030,2,1,,17389859,6214,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
102,1188,1,2,,48414928,6214,Active,,,,,DSSTox (EPAFHM) EPA Fathead Minnow Acute Toxicity,Other,,
103,1189,1,5,,48413846,6214,Active,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary SingleCellCall Results,Other,,
104,1194,1,3,,48413846,6214,Inactive,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Salmonella Mutagenicity,Other,,
105,1199,1,3,,48413846,6214,Active,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary Mouse Bioassay Results,Other,,
106,1205,1,4,,48413846,6214,Active,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary MultiCellCall Results,Other,,
107,1208,1,3,,48413846,6214,Active,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary Rat Bioassay Results,Other,,
108,1452,1,1,,17389859,6214,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
109,1457,1,1,,17389859,6214,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
110,1458,1,1,,17389859,6214,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
111,1469,1,1,,17389859,6214,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
112,1471,2,1,,17389859,6214,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
113,1476,2,1,,17389859,6214,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
114,1477,1,1,,17389859,6214,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
115,1478,2,1,,17389859,6214,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
116,1479,1,2,,17389859,6214,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
117,1948,1,1,,17389859,6214,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
118,2101,1,1,,17389859,6214,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
119,2107,1,1,,17389859,6214,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
120,2112,1,1,,17389859,6214,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
121,2120,1,1,,17389859,6214,Inactive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Inducers of Hypoxia Response,Confirmatory,,
122,2517,2,1,,17389859,6214,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
123,2546,1,1,,17389859,6214,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
124,2549,1,1,,17389859,6214,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
125,2551,1,1,,17389859,6214,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
126,19825,3,3,,103407618,6214,Unspecified,,,,,Partition coefficient (logP),Other,7861411.0,
127,37563,3,3,,103407618,6214,Unspecified,,,,,Aneuploidy activity was determined; - indicates negative induction of aneuploidy in Aspergillus nidulans,Other,7861411.0,
128,433903,3,3,,103407618,6214,Unspecified,,,,,Hepatotoxicity in mouse assessed as carcinogenic potency,Other,19272677.0,
129,485290,1,1,,17389859,6214,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
130,588513,1,1,,17389859,6214,Inactive,348019627.0,2099.0,,Potency,qHTS assay for small molecule antagonists of estrogen receptor alpha signaling,Confirmatory,,
131,588514,1,1,,17389859,6214,Inactive,348019627.0,2099.0,,Potency,qHTS assay for small molecule agonists of estrogen receptor alpha signaling,Confirmatory,,
132,588515,1,1,,17389859,6214,Inactive,124375976.0,367.0,,Potency,qHTS assay for small molecule agonists of androgen receptor signaling,Confirmatory,,
133,588516,1,1,,17389859,6214,Inactive,124375976.0,367.0,,Potency,qHTS assay for small molecule antagonists of androgen receptor signaling,Confirmatory,,
134,588526,1,1,,17389859,6214,Inactive,325495553.0,9971.0,,Potency,qHTS assay for small molecule antagonists of farnesoid X receptor signaling,Confirmatory,,
135,588527,1,1,,17389859,6214,Inactive,325495553.0,9971.0,,Potency,qHTS assay for small molecule agonists of farnesoid X receptor signaling,Confirmatory,,
136,588532,1,1,,17389859,6214,Inactive,311348376.0,2908.0,,Potency,qHTS assay for small molecule agonists of glucocorticoid receptor signaling,Confirmatory,,
137,588533,1,1,,17389859,6214,Inactive,311348376.0,2908.0,,Potency,qHTS assay for small molecule antagonists of glucocorticoid receptor signaling,Confirmatory,,
138,588534,1,1,,17389859,6214,Inactive,216409690.0,5467.0,,Potency,qHTS assay for small molecule agonists of peroxisome proliferator-activated receptor delta signaling,Confirmatory,,
139,588535,1,1,,17389859,6214,Inactive,216409690.0,5467.0,,Potency,qHTS assay for small molecule antagonists of peroxisome proliferator-activated receptor delta signaling,Confirmatory,,
140,588536,1,1,,17389859,6214,Inactive,216409692.0,5468.0,,Potency,qHTS assay for small molecule agonists of peroxisome proliferator-activated receptor gamma signaling,Confirmatory,,
141,588537,1,1,,17389859,6214,Inactive,216409692.0,5468.0,,Potency,qHTS assay for small molecule antagonists of peroxisome proliferator-activated receptor gamma signaling,Confirmatory,,
142,588541,1,1,,17389859,6214,Inactive,216409708.0,7421.0,,Potency,qHTS assay for small molecule antagonists of vitamin D receptor signaling,Confirmatory,,
143,588543,1,1,,17389859,6214,Inactive,216409708.0,7421.0,,Potency,qHTS assay for small molecule agonists of vitamin D receptor signaling,Confirmatory,,
144,588544,1,1,,17389859,6214,Inactive,325495497.0,6256.0,,Potency,qHTS assay for small molecule agonists of retinoid X receptor alpha signaling,Confirmatory,,
145,588545,1,1,,17389859,6214,Inactive,189491771.0,7068.0,,Potency,qHTS assay for small molecule agonists of thyroid hormone receptor beta signaling,Confirmatory,,
146,588546,1,1,,17389859,6214,Inactive,325495497.0,6256.0,,Potency,qHTS assay for small molecule antagonists of retinoid X receptor alpha signaling,Confirmatory,,
147,588547,1,1,,17389859,6214,Inactive,189491771.0,7068.0,,Potency,qHTS assay for small molecule antagonists of thyroid hormone receptor beta signaling,Confirmatory,,
148,588834,2,1,,17389859,6214,Inconclusive,325651834.0,3757.0,39.8107,Potency,qHTS Assay for Small Molecule Inhibitors of the Human hERG Channel Activity,Confirmatory,,
149,651631,4,1,,144207922,6214,Inactive,269849759.0,7157.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
150,651632,4,1,,144207922,6214,Inactive,296439460.0,79915.0,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
151,651633,4,1,,144207922,6214,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
152,651634,4,1,,144207922,6214,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
153,651741,1,1,,17389859,6214,Inconclusive,20149576.0,4780.0,0.0211,Potency,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
154,651743,1,1,,17389859,6214,Inactive,269849759.0,7157.0,,Potency,qHTS assay for small molecule activators of the p53 signaling pathway,Confirmatory,,
155,651749,1,1,,17389859,6214,Inactive,34577122.0,4790.0,,Potency,qHTS assay for small molecule activators of the nuclear factor-kappa B (NF-kB) signaling pathway,Confirmatory,,
156,651751,1,1,,17389859,6214,Inactive,5702233.0,84385.0,,Potency,qHTS assay for small molecule activators of the rat pregnane X receptor (rPXR) signaling pathway,Confirmatory,,
157,651754,1,1,,17389859,6214,Inactive,,,,Potency,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - 1 hr assay,Confirmatory,,
158,651755,1,1,,17389859,6214,Inactive,,,,Potency,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - 5 hr assay,Confirmatory,,
159,651757,1,1,,17389859,6214,Inactive,25952111.0,7124.0,,Potency,qHTS assay to identify small molecules that stimulate Tumor Necrosis Factor-alpha (TNF-alpha) secretion,Confirmatory,,
160,651758,1,1,,17389859,6214,Inactive,186368.0,3576.0,,Potency,qHTS assay to identify small molecules that stimulate interleukin-8 (IL-8) secretion,Confirmatory,,
161,651777,1,1,,17389859,6214,Inactive,51095037.0,196.0,,Potency,qHTS assay for environmental chemicals that activate the Aryl hydrocarbon Receptor (AhR) signaling pathway,Confirmatory,,
162,651778,1,1,,17389859,6214,Inactive,3041727.0,5465.0,,Potency,qHTS assay for small molecule agonists of the peroxisome proliferator-activated receptor alpha (PPARalpha) signaling pathway,Confirmatory,,
163,651802,1,1,,17389859,6214,Inactive,49066040.0,6097.0,6.6824,Potency,qHTS assay for small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
164,651838,1,1,,17389859,6214,Unspecified,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
165,651838,1,1,1.0,17389859,6214,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
166,651838,1,1,2.0,17389859,6214,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
167,651838,1,1,3.0,17389859,6214,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
168,651838,1,1,4.0,17389859,6214,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
169,651838,1,1,5.0,17389859,6214,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
170,651838,1,1,6.0,17389859,6214,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
171,651838,1,1,7.0,17389859,6214,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
172,651838,1,1,8.0,17389859,6214,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
173,720516,2,1,,144207922,6214,Inactive,296439460.0,79915.0,,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
174,720552,2,1,,144207922,6214,Inactive,269849759.0,7157.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
175,720634,2,1,,144207922,6214,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
176,720635,2,1,,144207922,6214,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
177,720636,1,1,,17389859,6214,Inactive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway measured by Nrf2-dependant transcriptional activity,Confirmatory,,
178,720637,2,1,,144207922,6214,Inactive,,,,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
179,720652,1,1,,17389859,6214,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
180,720653,1,1,,17389859,6214,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway measured by Nrf2-dependant transcriptional activity - cell viability counter screen,Confirmatory,,
181,720659,1,1,,17389859,6214,Inactive,325495557.0,8856.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the human pregnane X receptor (PXR) signaling pathway,Confirmatory,,
182,720674,2,2,,144207922,6214,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
183,720675,2,2,,144207922,6214,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
184,720678,2,1,,144207922,6214,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
185,720679,2,1,,144207922,6214,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
186,720680,2,1,,144207922,6214,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
187,720681,2,1,,144207922,6214,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
188,720682,2,1,,144207922,6214,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
189,720683,2,1,,144207922,6214,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
190,720684,2,1,,144207922,6214,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
191,720685,2,1,,144207922,6214,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
192,720686,2,1,,144207922,6214,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
193,720687,2,2,,144207922,6214,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
194,720691,4,1,,144207922,6214,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
195,720692,3,1,,144207922,6214,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
196,720693,3,1,,144207922,6214,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
197,720719,2,1,,144207922,6214,Inactive,311348376.0,2908.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
198,720725,2,1,,144207922,6214,Inactive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
199,743012,3,1,,144207922,6214,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
200,743014,3,1,,144207922,6214,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
201,743015,3,1,,144207922,6214,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
202,743033,3,1,,144207922,6214,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
203,743035,2,1,,144207922,6214,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
204,743036,2,1,,144207922,6214,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
205,743040,3,1,,144207922,6214,Inconclusive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
206,743041,3,1,,144207922,6214,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
207,743042,3,1,,144207922,6214,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
208,743053,2,1,,144207922,6214,Inconclusive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
209,743054,2,1,,144207922,6214,Inactive,124375976.0,367.0,,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
210,743063,2,1,,144207922,6214,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
211,743064,3,1,,144207922,6214,Inconclusive,,,27.6674,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
212,743065,3,1,,144207922,6214,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
213,743066,3,1,,144207922,6214,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
214,743067,2,1,,144207922,6214,Inactive,399498506.0,24831.0,,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
215,743069,2,1,,144207922,6214,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
216,743074,2,1,,144207922,6214,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
217,743075,2,1,,144207922,6214,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
218,743077,2,1,,144207922,6214,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
219,743078,2,1,,144207922,6214,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
220,743079,3,1,,144207922,6214,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
221,743080,3,1,,144207922,6214,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
222,743081,3,1,,144207922,6214,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
223,743083,3,1,,144207922,6214,Inactive,119597822.0,1588.0,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
224,743084,3,1,,144207922,6214,Inactive,,,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
225,743085,3,1,,144207922,6214,Inactive,51095037.0,196.0,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
226,743086,3,1,,144207922,6214,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
227,743091,2,1,,144207922,6214,Inactive,348019627.0,2099.0,,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
228,743094,3,1,,144207922,6214,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
229,743122,2,1,,144207922,6214,Inconclusive,51095037.0,196.0,,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
230,743139,2,1,,144207922,6214,Inactive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
231,743140,2,1,,144207922,6214,Inactive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
232,743191,3,1,,144207922,6214,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
233,743194,3,1,,144207922,6214,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen,Confirmatory,,
234,743199,2,1,,144207922,6214,Inactive,216409692.0,5468.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
235,743202,4,1,,144207922,6214,Inactive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
236,743203,3,1,,144207922,6214,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen,Confirmatory,,
237,743209,3,1,,144207922,6214,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen,Confirmatory,,
238,743210,4,1,,144207922,6214,Inactive,4504517.0,3315.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway,Confirmatory,,
239,743211,3,1,,144207922,6214,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
240,743212,3,1,,144207922,6214,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
241,743213,3,1,,144207922,6214,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
242,743215,3,1,,144207922,6214,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
243,743217,3,1,,144207922,6214,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
244,743218,3,1,,144207922,6214,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
245,743219,3,1,,144207922,6214,Inactive,20149576.0,4780.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary,Summary,,
246,743220,3,1,,144207922,6214,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
247,743221,3,1,,144207922,6214,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
248,743222,3,1,,144207922,6214,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
249,743223,3,1,,144207922,6214,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
250,743224,3,1,,144207922,6214,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
251,743225,3,1,,144207922,6214,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
252,743226,2,1,,144207922,6214,Inactive,216409690.0,5467.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
253,743227,2,1,,144207922,6214,Inactive,216409690.0,5467.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
254,743228,3,1,,144207922,6214,Inactive,4504517.0,3315.0,,Ratio Potency (uM),qHTS assay for small molecule activators of the heat shock response signaling pathway: Summary,Summary,,
255,743239,2,1,,144207922,6214,Inactive,325495553.0,9971.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
256,743240,2,1,,144207922,6214,Inactive,325495553.0,9971.0,,,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
257,743241,2,1,,144207922,6214,Inactive,216409708.0,7421.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
258,743242,2,1,,144207922,6214,Inactive,216409708.0,7421.0,,,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
259,743288,1,1,,17389859,6214,Inactive,,,,Potency,qHTS assay for cell viability of HEK293 cells,Confirmatory,,
260,743292,1,1,,17389859,6214,Inactive,,,,Potency,qHTS assay for cell viability of the p53RE-bla HCT-116 cell line,Confirmatory,,
261,931921,1,3,,103407618,6214,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: R040722,Other,,
262,931922,1,3,,103407618,6214,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: R040722,Other,,
263,931923,1,3,,103407618,6214,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: R040722,Other,,
264,931924,1,3,,103407618,6214,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: R040722,Other,,
265,931925,1,3,,103407618,6214,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: R040722,Other,,
266,931926,1,3,,103407618,6214,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: R040722,Other,,
267,931927,1,3,,103407618,6214,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: R040722,Other,,
268,931928,1,3,,103407618,6214,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: R040722,Other,,
269,931929,1,3,,103407618,6214,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: R040722,Other,,
270,931930,1,3,,103407618,6214,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: R040722,Other,,
271,931931,1,3,,103407618,6214,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: R040722,Other,,
272,931932,1,3,,103407618,6214,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: R040722,Other,,
273,932561,1,3,,103407618,6214,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: R040722,Other,,
274,948693,1,3,,103407618,6214,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: R040722,Other,,
275,949203,1,3,,103407618,6214,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: R040722,Other,,
276,949204,1,3,,103407618,6214,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: R040722,Other,,
277,949205,1,3,,103407618,6214,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: R040722,Other,,
278,949206,1,3,,103407618,6214,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: R040722,Other,,
279,949207,1,3,,103407618,6214,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: R040722,Other,,
280,949208,1,3,,103407618,6214,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: R040722,Other,,
281,949209,1,3,,103407618,6214,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: R040722,Other,,
282,949210,1,3,,103407618,6214,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: R040722,Other,,
283,949211,1,3,,103407618,6214,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: R040722,Other,,
284,949212,1,3,,103407618,6214,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: R040722,Other,,
285,949213,1,3,,103407618,6214,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: R040722,Other,,
286,949214,1,3,,103407618,6214,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: R040722,Other,,
287,964858,1,3,,103407618,6214,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: R040722,Other,,
288,964859,1,3,,103407618,6214,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: R040722,Other,,
289,964860,1,3,,103407618,6214,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: R040722,Other,,
290,964861,1,3,,103407618,6214,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: R040722,Other,,
291,965240,1,3,,103407618,6214,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: R040722,Other,,
292,965241,1,3,,103407618,6214,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: R040722,Other,,
293,965242,1,3,,103407618,6214,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: R040722,Other,,
294,966638,1,3,,103407618,6214,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: R040722,Other,,
295,966639,1,3,,103407618,6214,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: R040722,Other,,
296,966640,1,3,,103407618,6214,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: R040722,Other,,
297,966641,1,3,,103407618,6214,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: R040722,Other,,
298,966642,1,3,,103407618,6214,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: R040722,Other,,
299,966643,1,3,,103407618,6214,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: R040722,Other,,
300,966644,1,3,,103407618,6214,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: R040722,Other,,
301,966645,1,3,,103407618,6214,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: R040722,Other,,
302,966646,1,3,,103407618,6214,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: R040722,Other,,
303,966647,1,3,,103407618,6214,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: R040722,Other,,
304,966648,1,3,,103407618,6214,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: R040722,Other,,
305,966649,1,3,,103407618,6214,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: R040722,Other,,
306,968258,1,3,,103407618,6214,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: R040722,Other,,
307,968259,1,3,,103407618,6214,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: R040722,Other,,
308,968260,1,3,,103407618,6214,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: R040722,Other,,
309,968261,1,3,,103407618,6214,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: R040722,Other,,
310,968262,1,3,,103407618,6214,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: R040722,Other,,
311,970286,1,3,,103407618,6214,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: R040722,Other,,
312,970287,1,3,,103407618,6214,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: R040722,Other,,
313,970288,1,3,,103407618,6214,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: R040722,Other,,
314,970289,1,3,,103407618,6214,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: R040722,Other,,
315,970920,1,3,,103407618,6214,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: R040722,Other,,
316,970921,1,3,,103407618,6214,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: R040722,Other,,
317,970922,1,3,,103407618,6214,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: R040722,Other,,
318,970923,1,3,,103407618,6214,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: R040722,Other,,
319,970924,1,3,,103407618,6214,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: R040722,Other,,
320,970925,1,3,,103407618,6214,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: R040722,Other,,
321,970926,1,3,,103407618,6214,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: R040722,Other,,
322,970927,1,3,,103407618,6214,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: R040722,Other,,
323,970928,1,3,,103407618,6214,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: R040722,Other,,
324,970929,1,3,,103407618,6214,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: R040722,Other,,
325,1016343,1,3,,103407618,6214,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Single Hepatocyte Necrosis; Study_ID: R040722,Other,,
326,1016344,1,3,,103407618,6214,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Fibrosis; Study_ID: R040722",Other,,
327,1016345,1,3,,103407618,6214,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Papillary Muscle, Cellular Infiltrate, Mixed Cell; Study_ID: R040722",Other,,
328,1016346,1,3,,103407618,6214,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Atrium, Cellular Infiltrate, Mononuclear Cell; Study_ID: R040722",Other,,
329,1016347,1,3,,103407618,6214,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Vacuolation; Study_ID: R040722",Other,,
330,1016348,1,3,,103407618,6214,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Interstitium, Fibrosis; Study_ID: R040722",Other,,
331,1016349,1,3,,103407618,6214,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Mineralization; Study_ID: R040722",Other,,
332,1016350,1,3,,103407618,6214,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Cyst(S); Study_ID: R040722",Other,,
333,1016351,1,3,,103407618,6214,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Epicardium, Hyperplasia; Study_ID: R040722",Other,,
334,1016352,1,3,,103407618,6214,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Cellular Infiltrate, Mononuclear Cell; Study_ID: R040722",Other,,
335,1016353,1,3,,103407618,6214,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Necrosis, Fibrinoid; Study_ID: R040722",Other,,
336,1016354,1,3,,103407618,6214,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Perivascular Fibrosis; Study_ID: R040722",Other,,
337,1016355,1,3,,103407618,6214,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nuclear Cytoplasmic Condensation; Study_ID: R040722,Other,,
338,1016356,1,3,,103407618,6214,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Dilatation; Study_ID: R040722",Other,,
339,1016357,1,3,,103407618,6214,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Cellular Infiltrate, Mononuclear Cell; Study_ID: R040722",Other,,
340,1016358,1,3,,103407618,6214,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Myocyte, Degeneration; Study_ID: R040722",Other,,
341,1016359,1,3,,103407618,6214,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Inflammation, Subacute; Study_ID: R040722",Other,,
342,1016360,1,3,,103407618,6214,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Urothelial Hyperplasia; Study_ID: R040722",Other,,
343,1016361,1,3,,103407618,6214,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Cellular Infiltrate, Mononuclear Cell; Study_ID: R040722",Other,,
344,1016362,1,3,,103407618,6214,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Papillary Muscle, Cellular Infiltrate, Mononuclear Cell; Study_ID: R040722",Other,,
345,1016363,1,3,,103407618,6214,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Deposit; Study_ID: R040722",Other,,
346,1016364,1,3,,103407618,6214,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Dilatation; Study_ID: R040722",Other,,
347,1016365,1,3,,103407618,6214,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Hyaline Droplets; Study_ID: R040722",Other,,
348,1016366,1,3,,103407618,6214,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Necrosis; Study_ID: R040722",Other,,
349,1016367,1,3,,103407618,6214,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Endocardium, Cellular Infiltrate, Mononuclear Cell; Study_ID: R040722",Other,,
350,1016368,1,3,,103407618,6214,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Tunica Media, Hypertrophy; Study_ID: R040722",Other,,
351,1016369,1,3,,103407618,6214,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Cyst(S); Study_ID: R040722",Other,,
352,1016951,1,3,,103407618,6214,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Atrium, Myocyte, Degeneration; Study_ID: R040722",Other,,
353,1016952,1,3,,103407618,6214,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Cellular Infiltrate, Mixed Cell; Study_ID: R040722",Other,,
354,1016953,1,3,,103407618,6214,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Cyst(S); Study_ID: R040722",Other,,
355,1016954,1,3,,103407618,6214,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Regeneration; Study_ID: R040722",Other,,
356,1016955,1,3,,103407618,6214,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Cellular Infiltrate, Mixed Cell; Study_ID: R040722",Other,,
357,1016956,1,3,,103407618,6214,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Fibrosis; Study_ID: R040722",Other,,
358,1016957,1,3,,103407618,6214,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Myocyte, Degeneration; Study_ID: R040722",Other,,
359,1016958,1,3,,103407618,6214,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Cellular Infiltrate, Mixed Cell; Study_ID: R040722",Other,,
360,1016959,1,3,,103407618,6214,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Cast, Proteinaceous; Study_ID: R040722",Other,,
361,1023775,1,3,,103407618,6214,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Epicardium, Cellular Infiltrate, Mixed Cell; Study_ID: R040722",Other,,
362,1023776,1,3,,103407618,6214,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Epicardium, Cellular Infiltrate, Mononuclear Cell; Study_ID: R040722",Other,,
363,1023777,1,3,,103407618,6214,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Autolysis; Study_ID: R040722,Other,,
364,1023778,1,3,,103407618,6214,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Atrium, Fibrosis; Study_ID: R040722",Other,,
365,1023779,1,3,,103407618,6214,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Papillary Muscle, Myocyte, Degeneration; Study_ID: R040722",Other,,
366,1023780,1,3,,103407618,6214,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Cellular Infiltrate, Mononuclear Cell; Study_ID: R040722",Other,,
367,1023781,1,3,,103407618,6214,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Infiltrative Cell, Polymorphonuclear Cell; Study_ID: R040722",Other,,
368,1023782,1,3,,103407618,6214,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Infiltrative Cell, Mononuclear Cell; Study_ID: R040722",Other,,
369,1023783,1,3,,103407618,6214,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Mineralization; Study_ID: R040722",Other,,
370,1023784,1,3,,103407618,6214,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Tubule, Regeneration; Study_ID: R040722",Other,,
371,1023785,1,3,,103407618,6214,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Fibrosis; Study_ID: R040722",Other,,
372,1023786,1,3,,103407618,6214,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Tubule, Dilatation; Study_ID: R040722",Other,,
373,1023787,1,3,,103407618,6214,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Nephropathy; Study_ID: R040722,Other,,
374,1023788,1,3,,103407618,6214,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Cellular Infiltrate, Mixed Cell; Study_ID: R040722",Other,,
375,1023789,1,3,,103407618,6214,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Atrium, Cellular Infiltrate, Mononuclear Cell; Study_ID: R040722",Other,,
376,1024372,1,3,,103407618,6214,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Myocyte, Degeneration; Study_ID: R040722",Other,,
377,1024373,1,3,,103407618,6214,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Myocyte, Lipid Accumulation; Study_ID: R040722",Other,,
378,1024374,1,3,,103407618,6214,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Interstitium, Inflammation, Chronic; Study_ID: R040722",Other,,
379,1024375,1,3,,103407618,6214,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Mineralization; Study_ID: R040722",Other,,
380,1024376,1,3,,103407618,6214,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Necrosis; Study_ID: R040722",Other,,
381,1024377,1,3,,103407618,6214,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Degeneration; Study_ID: R040722",Other,,
382,1024378,1,3,,103407618,6214,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Perivascular Edema; Study_ID: R040722",Other,,
383,1025853,1,3,,103407618,6214,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Epicardium, Cellular Infiltrate, Mixed Cell; Study_ID: R040722",Other,,
384,1025854,1,3,,103407618,6214,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Epicardium, Cellular Infiltrate, Mononuclear Cell; Study_ID: R040722",Other,,
385,1025855,1,3,,103407618,6214,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Autolysis; Study_ID: R040722,Other,,
386,1025856,1,3,,103407618,6214,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Atrium, Fibrosis; Study_ID: R040722",Other,,
387,1025857,1,3,,103407618,6214,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Papillary Muscle, Myocyte, Degeneration; Study_ID: R040722",Other,,
388,1025858,1,3,,103407618,6214,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Cellular Infiltrate, Mononuclear Cell; Study_ID: R040722",Other,,
389,1025859,1,3,,103407618,6214,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Infiltrative Cell, Polymorphonuclear Cell; Study_ID: R040722",Other,,
390,1025860,1,3,,103407618,6214,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Infiltrative Cell, Mononuclear Cell; Study_ID: R040722",Other,,
391,1025861,1,3,,103407618,6214,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Mineralization; Study_ID: R040722",Other,,
392,1025862,1,3,,103407618,6214,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Tubule, Regeneration; Study_ID: R040722",Other,,
393,1025863,1,3,,103407618,6214,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Fibrosis; Study_ID: R040722",Other,,
394,1025864,1,3,,103407618,6214,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Tubule, Dilatation; Study_ID: R040722",Other,,
395,1025865,1,3,,103407618,6214,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Nephropathy; Study_ID: R040722,Other,,
396,1025866,1,3,,103407618,6214,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Cellular Infiltrate, Mixed Cell; Study_ID: R040722",Other,,
397,1025867,1,3,,103407618,6214,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Atrium, Cellular Infiltrate, Mononuclear Cell; Study_ID: R040722",Other,,
398,1025868,1,3,,103407618,6214,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Myocyte, Degeneration; Study_ID: R040722",Other,,
399,1025869,1,3,,103407618,6214,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Myocyte, Lipid Accumulation; Study_ID: R040722",Other,,
400,1025870,1,3,,103407618,6214,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Interstitium, Inflammation, Chronic; Study_ID: R040722",Other,,
401,1025871,1,3,,103407618,6214,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Mineralization; Study_ID: R040722",Other,,
402,1025872,1,3,,103407618,6214,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Necrosis; Study_ID: R040722",Other,,
403,1025873,1,3,,103407618,6214,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Degeneration; Study_ID: R040722",Other,,
404,1026456,1,3,,103407618,6214,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Perivascular Edema; Study_ID: R040722",Other,,
405,1026457,1,3,,103407618,6214,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Single Hepatocyte Necrosis; Study_ID: R040722,Other,,
406,1026458,1,3,,103407618,6214,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Fibrosis; Study_ID: R040722",Other,,
407,1026459,1,3,,103407618,6214,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Papillary Muscle, Cellular Infiltrate, Mixed Cell; Study_ID: R040722",Other,,
408,1026460,1,3,,103407618,6214,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Atrium, Cellular Infiltrate, Mononuclear Cell; Study_ID: R040722",Other,,
409,1026461,1,3,,103407618,6214,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Vacuolation; Study_ID: R040722",Other,,
410,1026462,1,3,,103407618,6214,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Interstitium, Fibrosis; Study_ID: R040722",Other,,
411,1026463,1,3,,103407618,6214,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Mineralization; Study_ID: R040722",Other,,
412,1026464,1,3,,103407618,6214,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Cyst(S); Study_ID: R040722",Other,,
413,1026465,1,3,,103407618,6214,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Epicardium, Hyperplasia; Study_ID: R040722",Other,,
414,1026466,1,3,,103407618,6214,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Cellular Infiltrate, Mononuclear Cell; Study_ID: R040722",Other,,
415,1026467,1,3,,103407618,6214,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Necrosis, Fibrinoid; Study_ID: R040722",Other,,
416,1026468,1,3,,103407618,6214,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Perivascular Fibrosis; Study_ID: R040722",Other,,
417,1026469,1,3,,103407618,6214,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nuclear Cytoplasmic Condensation; Study_ID: R040722,Other,,
418,1026470,1,3,,103407618,6214,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Dilatation; Study_ID: R040722",Other,,
419,1026471,1,3,,103407618,6214,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Cellular Infiltrate, Mononuclear Cell; Study_ID: R040722",Other,,
420,1026472,1,3,,103407618,6214,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Myocyte, Degeneration; Study_ID: R040722",Other,,
421,1026473,1,3,,103407618,6214,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Inflammation, Subacute; Study_ID: R040722",Other,,
422,1028343,1,3,,103407618,6214,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Urothelial Hyperplasia; Study_ID: R040722",Other,,
423,1028344,1,3,,103407618,6214,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Cellular Infiltrate, Mononuclear Cell; Study_ID: R040722",Other,,
424,1028345,1,3,,103407618,6214,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Papillary Muscle, Cellular Infiltrate, Mononuclear Cell; Study_ID: R040722",Other,,
425,1028346,1,3,,103407618,6214,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Deposit; Study_ID: R040722",Other,,
426,1028347,1,3,,103407618,6214,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Dilatation; Study_ID: R040722",Other,,
427,1028348,1,3,,103407618,6214,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Hyaline Droplets; Study_ID: R040722",Other,,
428,1028349,1,3,,103407618,6214,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Necrosis; Study_ID: R040722",Other,,
429,1028350,1,3,,103407618,6214,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Endocardium, Cellular Infiltrate, Mononuclear Cell; Study_ID: R040722",Other,,
430,1028351,1,3,,103407618,6214,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Tunica Media, Hypertrophy; Study_ID: R040722",Other,,
431,1028352,1,3,,103407618,6214,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Cyst(S); Study_ID: R040722",Other,,
432,1028353,1,3,,103407618,6214,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Atrium, Myocyte, Degeneration; Study_ID: R040722",Other,,
433,1028354,1,3,,103407618,6214,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Cellular Infiltrate, Mixed Cell; Study_ID: R040722",Other,,
434,1028355,1,3,,103407618,6214,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Cyst(S); Study_ID: R040722",Other,,
435,1028356,1,3,,103407618,6214,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Regeneration; Study_ID: R040722",Other,,
436,1028357,1,3,,103407618,6214,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Cellular Infiltrate, Mixed Cell; Study_ID: R040722",Other,,
437,1028358,1,3,,103407618,6214,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Fibrosis; Study_ID: R040722",Other,,
438,1028359,1,3,,103407618,6214,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Myocyte, Degeneration; Study_ID: R040722",Other,,
439,1028360,1,3,,103407618,6214,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Cellular Infiltrate, Mixed Cell; Study_ID: R040722",Other,,
440,1028947,1,3,,103407618,6214,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Cast, Proteinaceous; Study_ID: R040722",Other,,
441,1159509,1,1,,144207922,6214,Inactive,119626539.0,4790.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway,Confirmatory,,
442,1159515,1,1,,144207922,6214,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway - cell viability counter screen,Confirmatory,,
443,1159516,1,1,,144207922,6214,Inactive,119611100.0,22926.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway,Confirmatory,,
444,1159517,1,1,,144207922,6214,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen,Confirmatory,,
445,1159518,1,1,,144207922,6214,Inactive,119626539.0,4790.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the NFkB signaling pathway: Summary,Summary,,
446,1159519,1,1,,144207922,6214,Inactive,119611100.0,22926.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway: Summary,Summary,,
447,1159520,1,1,,144207922,6214,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
448,1159521,1,1,,144207922,6214,Inactive,15928672.0,19885.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
449,1159523,1,1,,144207922,6214,Inactive,15928672.0,19885.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,Summary,,
450,1159525,1,1,,144207922,6214,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway - cell viability counter screen,Confirmatory,,
451,1159526,1,1,,144207922,6214,Inactive,119627033.0,3725.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway,Confirmatory,,
452,1159527,1,1,,144207922,6214,Inactive,325495497.0,6256.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway,Confirmatory,,
453,1159528,1,1,,144207922,6214,Inactive,119627033.0,3725.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the AP-1 signaling pathway: Summary,Summary,,
454,1159529,1,1,,144207922,6214,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,Confirmatory,,
455,1159531,1,1,,144207922,6214,Inactive,325495497.0,6256.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,Summary,,
456,1159551,1,1,,144207922,6214,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid acid receptor (RAR) signaling pathway - cell viability counter screen,Confirmatory,,
457,1159552,1,1,,144207922,6214,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
458,1159553,2,1,,144207922,6214,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
459,1159555,1,1,,144207922,6214,Inactive,325495463.0,5914.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,Summary,,
460,1224834,3,1,,144207922,6214,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,Confirmatory,,
461,1224835,1,1,,144207922,6214,Inactive,160794.0,,,Potency-Replicate_1,qHTS assay to identify small molecule inhibitors of firefly luciferase,Confirmatory,,
462,1224836,1,1,,144207922,6214,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
463,1224837,1,1,,144207922,6214,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
464,1224838,1,1,,144207922,6214,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
465,1224839,1,1,,144207922,6214,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
466,1224840,3,1,,144207922,6214,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,Confirmatory,,
467,1224841,3,1,,144207922,6214,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
468,1224842,3,1,,144207922,6214,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
469,1224843,1,1,,144207922,6214,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
470,1224844,1,1,,144207922,6214,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway - cell viability counter screen,Confirmatory,,
471,1224845,1,1,,144207922,6214,Inactive,344243002.0,100757539.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX,Confirmatory,,
472,1224846,1,1,,144207922,6214,Inactive,11995455.0,3091.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway,Confirmatory,,
473,1224847,1,1,,144207922,6214,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,Confirmatory,,
474,1224848,3,1,,144207922,6214,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
475,1224849,3,1,,144207922,6214,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
476,1224867,1,1,,144207922,6214,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,Confirmatory,,
477,1224868,1,1,,144207922,6214,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,Confirmatory,,
478,1224869,1,1,,144207922,6214,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 0 hour,Confirmatory,,
479,1224870,1,1,,144207922,6214,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,Confirmatory,,
480,1224871,1,1,,144207922,6214,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,Confirmatory,,
481,1224872,1,1,,144207922,6214,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,Confirmatory,,
482,1224873,1,1,,144207922,6214,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,Confirmatory,,
483,1224874,1,1,,144207922,6214,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,Confirmatory,,
484,1224875,1,1,,144207922,6214,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,Confirmatory,,
485,1224876,1,1,,144207922,6214,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,Confirmatory,,
486,1224877,1,1,,144207922,6214,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,Confirmatory,,
487,1224878,1,1,,144207922,6214,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,Confirmatory,,
488,1224879,1,1,,144207922,6214,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,Confirmatory,,
489,1224880,1,1,,144207922,6214,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,Confirmatory,,
490,1224881,1,1,,144207922,6214,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,Confirmatory,,
491,1224882,1,1,,144207922,6214,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 0 hour,Confirmatory,,
492,1224883,1,1,,144207922,6214,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,Confirmatory,,
493,1224884,1,1,,144207922,6214,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,Confirmatory,,
494,1224885,1,1,,144207922,6214,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,Confirmatory,,
495,1224886,1,1,,144207922,6214,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,Confirmatory,,
496,1224887,1,1,,144207922,6214,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,Confirmatory,,
497,1224888,1,1,,144207922,6214,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,Confirmatory,,
498,1224889,1,1,,144207922,6214,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,Confirmatory,,
499,1224890,1,1,,144207922,6214,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,Confirmatory,,
500,1224892,1,1,,144207922,6214,Inactive,66775687.0,9970.0,,,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
501,1224893,1,1,,144207922,6214,Inactive,66775687.0,9970.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
502,1224894,1,1,,144207922,6214,Inactive,11995455.0,3091.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway: Summary,Summary,,
503,1224895,1,1,,144207922,6214,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
504,1224896,1,1,,144207922,6214,Inactive,344243002.0,100757539.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of H2AX: Summary,Summary,,
505,1259241,1,1,,144207922,6214,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,Confirmatory,,
506,1259242,1,1,,144207922,6214,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,Confirmatory,,
507,1259243,1,1,,144207922,6214,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,Confirmatory,,
508,1259244,1,1,,144207922,6214,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,Confirmatory,,
509,1259247,1,1,,144207922,6214,Inactive,124375976.0,367.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,Summary,,
510,1259248,1,1,,144207922,6214,Inactive,348019627.0,2099.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,Summary,,
511,1259364,1,1,,144207922,6214,Inactive,1013403374.0,9734.0,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors,Confirmatory,,
512,1259365,1,1,,144207922,6214,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors - cell viability counter screen,Confirmatory,,
513,1259366,1,1,,144207922,6214,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
514,1259367,1,1,,144207922,6214,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
515,1259368,1,1,,144207922,6214,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
516,1259369,1,1,,144207922,6214,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
517,1259377,1,1,,144207922,6214,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
518,1259378,1,1,,144207922,6214,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
519,1259379,1,1,,144207922,6214,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
520,1259380,1,1,,144207922,6214,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
521,1259381,1,1,,144207922,6214,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,Confirmatory,,
522,1259382,1,1,,144207922,6214,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
523,1259383,1,1,,144207922,6214,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,Confirmatory,,
524,1259384,1,1,,144207922,6214,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen,Confirmatory,,
525,1259385,1,1,,144207922,6214,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
526,1259386,1,1,,144207922,6214,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
527,1259387,1,1,,144207922,6214,Inactive,124375976.0,367.0,,,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,Summary,,
528,1259388,1,1,,144207922,6214,Inactive,1013403374.0,9734.0,,Antagonist Potency (uM),qHTS assay to identify small molecule HDAC inhibitors: Summary,Summary,,
529,1259390,1,1,,144207922,6214,Inactive,109731339.0,2737.0,,,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
530,1259391,1,1,,144207922,6214,Inactive,348019627.0,2099.0,,,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,Summary,,
531,1259392,1,1,,144207922,6214,Inactive,109731339.0,2737.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
532,1259393,1,1,,144207922,6214,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen: Summary,Summary,,
533,1259394,1,1,,144207922,6214,Inactive,54288833.0,2100.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
534,1259395,1,1,,144207922,6214,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
535,1259396,1,1,,144207922,6214,Inactive,54288833.0,2100.0,,,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
536,1259401,1,1,,144207922,6214,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
537,1259402,1,1,,144207922,6214,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
538,1259403,1,1,,144207922,6214,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
539,1259404,1,1,,144207922,6214,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
540,1259407,1,1,,363898280,6214,Inactive,,,,,CCRIS mutagenicity studies,Other,,
541,1259408,1,1,,363894954,6214,Inactive,,,,,GENE-TOX mutagenicity studies,Other,,
542,1259411,1,1,,363898280,6214,Inactive,,,,,CCRIS carcinogenicity studies,Other,,
